15:03 , Mar 1, 2018 |  BC Innovations  |  Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
20:23 , Jun 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified a piperazine-azaindoline-based dual BIRC2/XIAP antagonist that could help treat breast cancer and melanoma. Chemical synthesis and testing of piperazine-azaindoline analogs in cell-based activity assays yielded a compound that...
07:00 , Sep 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: X-linked inhibitor of apoptosis (XIAP); baculoviral IAP repeat-containing 2 (BIRC2; cIAP1)

Cancer INDICATION: Cancer In vitro and mouse studies identified a small molecule inhibitor of XIAP and BIRC2 that could help treat cancer. Fragment-based drug discovery identified a piperazine-based compound that inhibited XIAP and BIRC2 with IC50 values...
07:00 , Apr 2, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); X-linked inhibitor of apoptosis (XIAP)

Cancer INDICATION: Cancer In vitro and mouse studies identified a macrocylic antagonist of cIAP1 and XIAP that could help treat cancer. In vitro screening of a cyclic peptidomimetic library identified a lead compound that inhibited cIAP1 and...
08:00 , Feb 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); inhibitor of apoptosis (IAP); X-linked inhibitor of apoptosis (XIAP)

Cancer INDICATION: Cancer In vitro and mouse studies identified heterodimeric antagonists of IAP proteins that could help treat cancer. Chemical synthesis and in vitro enzymatic assays identified two lead antagonists that inhibited the BIR2 and BIR3 domains...
07:00 , May 30, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Baculoviral IAP repeat- containing 2 (BIRC2; cIAP1); cIAP2 (BIRC3); diablo homolog (DIABLO;...
08:00 , Feb 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); x-linked inhibitor of apoptosis (XIAP)...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

TL32711: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 24 evaluable patients with solid tumors or lymphoma showed that once-weekly 0.18-17.2 mg/m 2 doses of IV TL32711 for 3 consecutive weeks as part of a 4-week...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Baculoviral IAP repeat-containing 2 (BIRC2; cIAP1); BIRC3 (cIAP2); x-linked inhibitor of apoptosis...
07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Autoimmune; inflammatory disease Baculoviral...